GLP-1R (exendin)

Ongoing clinical trials and approved products targeting GLP-1R (exendin), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

4ongoing imaging trials

0approved products

Target note

Full name: GLP-1 receptor
Nature: G protein-coupled receptor of pancreatic β cells.
Normal expression: Pancreatic islets, kidneys (clearance).
Value: Localising benign insulinomas and focal lesions of hyperinsulinism, with higher sensitivity than other imaging; measuring β-cell mass.
Approaches: [68Ga]Ga-NODAGA-exendin-4, [68Ga]Ga-DOTA-exendin-4, [99mTc]exendin for SPECT.
Indications explored: Insulinoma, endogenous hyperinsulinism, nesidioblastosis, diabetes (research).
Points of caution: Intense renal uptake; malignant insulinomas express less GLP-1R (combine with SSTR imaging).

Ongoing imaging trials · 4Open in the radar →

Trial	Phase	Status	Sponsor	Countries
Labeled exendin (GLP-1R)NCT07398300 · Diabetes and obesity	No phase	Recruiting	Copenhagen University Hospital, Rigshospitalet	1
HBED-CC-PEG6-E · Labeled exendin (GLP-1R)NCT07808879 · Hyperinsulinism and insulinoma	No phase	Recruiting	Peking Union Medical College Hospital	1
Labeled exendin (GLP-1R)NCT05662189 · Hyperinsulinism and insulinoma	No phase	Recruiting	Azienda Ospedaliero-Universitaria di Parma	1
Honeymoon · Labeled exendin (GLP-1R)NCT03917238 · Diabetes and obesity	No phase	Active, not recruiting	Radboud University Medical Center	1

Cite this page

GLP-1R (exendin). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/glp-1r-exendin/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.